Cargando…
Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update
There have been major advances in the treatment of HBV and HCV with anti-viral treatments, which is reducing the prevalence of fibrosis due to these viruses and obviating the need for anti-fibrotic therapies in these diseases. At the same time, however, the prevalence of non-alcoholic fatty liver di...
Autores principales: | Huisman, Tsipora M, Dieterich, Douglas T, Friedman, Scott L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987269/ https://www.ncbi.nlm.nih.gov/pubmed/33776490 http://dx.doi.org/10.2147/JEP.S265286 |
Ejemplares similares
-
Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
por: Traber, Peter G., et al.
Publicado: (2013) -
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
por: O’Farrell, Marie, et al.
Publicado: (2022) -
Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021) -
Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis—Roles as Putative Treatment Targets?
por: Zisser, Alexandra, et al.
Publicado: (2021) -
Hepatic Stellate Cell-Immune Interactions in NASH
por: Carter, James K., et al.
Publicado: (2022)